Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak Pharmaceuticals. A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Rubella virus vaccine | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Calanolide A. |
| Bacillus calmette-guerin substrain tice live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Calanolide A. |
| Bacillus calmette-guerin substrain connaught live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Calanolide A. |
| Yellow fever vaccine | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Calanolide A. |
| Anthrax vaccine | The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Calanolide A. |
| Typhoid Vaccine Live | The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Calanolide A. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Calanolide A. |
| Human adenovirus e serotype 4 strain cl-68578 antigen | The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Calanolide A. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Calanolide A. |
| Adenovirus type 7 vaccine live | The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Calanolide A. |
| Varicella zoster vaccine (live/attenuated) | The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Calanolide A. |
| Bacillus calmette-guerin substrain russian BCG-I live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Calanolide A. |
| Dexmethylphenidate | The serum concentration of the active metabolites of Calanolide A can be increased when Calanolide A is used in combination with Dexmethylphenidate. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be increased when used in combination with Calanolide A. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be increased when used in combination with Calanolide A. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Calanolide A. |
| Tolazamide | The therapeutic efficacy of Tolazamide can be increased when used in combination with Calanolide A. |
| Glyburide | The therapeutic efficacy of Glyburide can be increased when used in combination with Calanolide A. |
| Glipizide | The therapeutic efficacy of Glipizide can be increased when used in combination with Calanolide A. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be increased when used in combination with Calanolide A. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be increased when used in combination with Calanolide A. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be increased when used in combination with Calanolide A. |
| Glisoxepide | The therapeutic efficacy of Glisoxepide can be increased when used in combination with Calanolide A. |
| Glibornuride | The therapeutic efficacy of Glibornuride can be increased when used in combination with Calanolide A. |
| Carbutamide | The therapeutic efficacy of Carbutamide can be increased when used in combination with Calanolide A. |
| Metahexamide | The therapeutic efficacy of Metahexamide can be increased when used in combination with Calanolide A. |
| Lepirudin | The risk or severity of bleeding can be increased when Calanolide A is combined with Lepirudin. |
| Doxycycline | The therapeutic efficacy of Calanolide A can be increased when used in combination with Doxycycline. |
| Diazoxide | The serum concentration of Calanolide A can be increased when it is combined with Diazoxide. |
| Chikungunya vaccine (live, attenuated) | The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Calanolide A. |
| Smallpox (Vaccinia) Vaccine, Live | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Calanolide A. |